Clinical Chemistry Forum. Crystal City, VA, USA, 1998/11/03.
The Food and Drug Administration (FDA) has been involved in the regulation of in vitro diagnostic devices (IVDs or laboratory tests) since the introduction of the Medical Device Amendments of 1976.
IVDs developed as kits or systems intended for use in multiple laboratories require review by the FDA before being marketed to ensure appropriate performance and labeling.
IVDs developed as in-house, or so-called « home-brew », tests or laboratory test services are considered medical devices, but historically have not been subject to premarket review as a matter of enforcement discretion.
FDA recently established a new regulatory paradigm for in-house tests based on classification of the active ingredients or building blocks of these tests as analyte-specific reagents (ASRs).
ASRs are exempt from premarket review but subject to both manufacturing and labeling controls.
Currently, genetic tests are received and reviewed by the FDA in the same manner as other in vitro diagnostic tests.
The FDA currently is in the process of chartering a new genetics advisory panel to provide the agency with outside expertise to deal with genetic testing issues.
We are also continuing to work with other agencies within the Department of Health and Human Services to determine how we can cooperatively help foster this important new area of testing.
Mots-clés Pascal : Maladie héréditaire, Diagnostic, Génétique, Food and Drug Administration, Réglementation, Essai, In vitro, Réactif analytique, Surveillance, Développement
Mots-clés Pascal anglais : Genetic disease, Diagnosis, Genetics, Food and Drug Administration, Regulation, Test, In vitro, Analytical reagent, Surveillance, Development
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0356924
Code Inist : 002B23A. Création : 14/12/1999.